Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (18)	2/8/1999 6:12:00 PM
From: Mike McFarland	Respond to of 438

I'd say very few except for the Gizzmo people and a handful of folks at Children's know. " Preclinical data pertaining to the protein and its antiangiogenic effects are not yet published. " And that's what makes it exciting, but also just a shot in the dark to buy, on this news alone. Actually, the p53 milestone payment is what put Genzyme Molecular Oncology on my list--Gizzmo could receive up to another 30M in payments in the years ahead...oh, let me just snip that in for newbies to the thread: "In addition to the $10 million received to date, Genzyme Molecular Oncology has the potential to receive up to an additional $30 million in patent, product development and sales milestone fees, in addition to royalties on product sales associated with Schering-Plough's development and commer- cialization of a p53 gene therapy product." Do I like the stock? Well let's see if it starts to run, I only have a trifling number of shares right now--enough so that I will pay attention and start putting together a little research folder on it. If I fall in love with the stock, you guys will know;-) (could be a good contrary indicator, hehheh)